<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03464019</url>
  </required_header>
  <id_info>
    <org_study_id>MSP-2017-1138</org_study_id>
    <nct_id>NCT03464019</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Etripamil for the Termination of Spontaneous PSVT. NODE-301</brief_title>
  <official_title>Multi-Centre, Randomized, Double-Blind, Placebo-Controlled, Efficacy, and Safety Study of Etripamil Nasal Spray for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia. The NODE-301 Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milestone Pharmaceuticals Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medpace, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Milestone Pharmaceuticals Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine whether etripamil nasal spray (NS) 70 mg
      is superior to placebo at terminating episodes of PSVT in an outpatient setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      NODE-301 is a multi-centre, randomized, double-blind, placebo-controlled study to evaluate
      the efficacy and safety of a nasal spray of etripamil, a new calcium channel blocker, in
      patients who experience an episode of paroxysmal ventricular tachycardia (PSVT).

      The study will comprise of 2 parts, Part 1 and Part 2. Part 1 will consist of patients that
      will be dosed with the double-blind study drug or have discontinued the study before the
      adjudication of the 150th positively adjudicated PSVT episode. The data from patients in Part
      1 will be cleaned and locked, on a per-patient basis, and will be included in pivotal
      analyses. Pivotal analyses will include safety; and primary, secondary, and exploratory
      efficacy analyses for Part 1 only. Patients in Part 1 will be unblinded after data is locked.

      Part 2 will consist of patients that will not be included in Part 1, i.e., Part 2 will
      consist of patients who were not dosed with the double-blind study drug or have not
      discontinued the study before the adjudication of the 150th positively adjudicated PSVT
      episode. The data from patients in Part 2 will be combined with that from Part 1 and will be
      included in exploratory analyses. Exploratory analyses will include safety; and primary,
      secondary, and exploratory efficacy analyses for Parts 1 and 2 combined. Patients in Part 2
      will be unblinded at the end of the study. Part 2 will end when one of the following criteria
      is met:

        -  75% of patients in Part 2 have completed the study (Final Study Visit), or

        -  Approximately 9 months after the date of the adjudication of the 150th positively
           adjudicated PSVT episode.

      Based on the results of the pivotal analyses from Part 1, the planned statistical analysis
      and conduct of Part 2 may be amended. However, in no case will the Part 2 dataset be
      integrated with the Part 1 pivotal dataset for primary efficacy or primary safety analyses.

      The study will include a Screening Visit, a Test Dose Randomization Visit, Follow-up Visits,
      a Treatment Period, and a Final Study Visit.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 18, 2018</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The time to conversion of an episode of PSVT to sinus rhythm (SR) after study drug administration.</measure>
    <time_frame>10 months</time_frame>
    <description>The primary efficacy endpoint is defined as an adjudicated termination of a positively adjudicated episode of PSVT (AV nodal reentrant tachycardia or AV reentrant tachycardia determination if possible) and conversion to sinus rhythm (SR) for at least 30 seconds.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relief of specific symptoms (i.e., heart palpitations, rapid pulse feeling, chest pain, anxiety, shortness of breath, dizziness, and fainting) potentially associated with an episode of PSVT.</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rating of Treatment Satisfaction Questionnaire for Medication (TSQM).</measure>
    <time_frame>10 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The number of positively adjudicated episodes of PSVT terminated by a vagal maneuver (VM).</measure>
    <time_frame>10 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The percentage of patients requiring additional medical intervention to terminate an episode of PSVT.</measure>
    <time_frame>10 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The repeat of key efficacy endpoints in various subgroups of interest (e.g., concomitant medications).</measure>
    <time_frame>10 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Paroxysmal Supraventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Etripamil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The dose of etripamil to be evaluated in NODE-301 is 70 mg. Patients will receive a total of 200 μL of etripamil Nasal Spray 70 via the Aptar Pharma Nasal Spray Bidose System.The devices will be prefilled and packaged into child-resistant boxes and instructions for its use will be provided in the study drug box.
The same formulation will be used for the Test Dose Randomization Visit and for the Treatment Period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients will receive a total of 200 μL of placebo via the Aptar Pharma Nasal Spray Bidose System.The devices will be prefilled and packaged into child-resistant boxes and instructions for its use will be provided in the study drug box.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etripamil</intervention_name>
    <description>Etripamil will be administered via the Aptar Pharma Nasal Spray Bidose System.</description>
    <arm_group_label>Etripamil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Aptar Pharma Nasal Spray</intervention_name>
    <description>Study drug and placebo will be administered via the Aptar Pharma Nasal Spray.</description>
    <arm_group_label>Etripamil</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients at least 18 years of age;

          2. Electrographically documented history of PSVT (e.g., electrocardiogram [ECG] obtained
             during an episode of PSVT, Holter monitoring, loop recorder, etc). If patient had a
             prior ablation for PSVT, patient must have documented ECG evidence of PSVT
             post-ablation;

          3. History of sustained episodes of PSVT (i.e., typically lasting approximately 20
             minutes or longer);

          4. Females of childbearing potential must agree to use an approved highly effective form
             of contraception from the time of signed informed consent until 30 days after the last
             administration of study drug and should have a negative serum pregnancy test result at
             the Screening Visit, a negative urine pregnancy test at the Test Dose Randomization
             Visit and must use an approved form of contraception between the 2 visits. Approved
             forms of contraception include hormonal intrauterine devices, hormonal contraceptives
             (oral birth control pills, Depo-Provera®, patch, or other injectables) together with
             supplementary double-barrier methods, such as condoms or diaphragms with spermicidal
             gel or foam.

             The following categories define females who are NOT considered to be of childbearing
             potential:

               -  Premenopausal females with 1 of the following:

                    1. Documented hysterectomy,

                    2. Documented bilateral salpingectomy, or

                    3. Documented bilateral oophorectomy, or

               -  Postmenopausal females, defined as having amenorrhea for at least 12 months
                  without an alternative medical cause;

          5. Males, except those who are surgically sterile, must use an approved highly effective
             form of contraception during the 3 days after any study drug administration; and

          6. Signed written informed consent.

        Exclusion Criteria:

        Patients who meet any of the following criteria will be excluded from participation in the
        study:

          1. Systolic blood pressure &lt;90 mmHg after a 5-minute rest in sitting position at the
             Screening Visit or before the test dose. In patients treated with a chronic
             prophylactic drug for PSVT (e.g., beta-blockers, verapamil, and diltiazem), the drug
             may be stopped for at least the equivalent of 5 half-lives and patients may be
             rescreened once;

          2. History of severe symptoms of hypotension, especially syncope, during episodes of
             PSVT;

          3. History of atrial arrhythmia that does not involve the AV node as part of the
             tachycardia circuit (e.g., atrial fibrillation, atrial flutter, intra-atrial
             tachycardia);

          4. History of allergic reaction to verapamil;

          5. Current therapy with digoxin or any Class I or III antiarrhythmic drug, except if
             these drugs are stopped at least the equivalent of 5 half-lives before the Test Dose
             Randomization Visit;

          6. Current therapy with amiodarone, or have taken amiodarone within 30 days prior to the
             Test Dose Randomization Visit;

          7. Evidence of ventricular pre-excitation (e.g., delta waves, short PR interval &lt;100
             msec, Wolff-Parkinson-White syndrome) on the ECG performed at the Screening Visit or
             before the test dose administration;

          8. Evidence of a second- or third-degree AV block on the ECG performed at the Screening
             Visit or before the test dose administration;

          9. History or evidence of severe ventricular arrhythmia (e.g., torsades de pointes,
             ventricular fibrillation, or sustained ventricular tachycardia);

         10. Current congestive heart failure defined by the New York Heart Association Class II to
             IV;

         11. Stroke in the last 6 months;

         12. Evidence of hepatic dysfunction defined as alanine aminotransferase or aspartate
             aminotransferase &gt;3 × the upper limit of normal (ULN) or total bilirubin &gt;2 × ULN at
             the Screening Visit, unless due to Gilbert syndrome;

         13. Evidence of renal dysfunction as determined by an estimated glomerular filtration rate
             assessed at the Screening Visit as follows:

               1. &lt;60 mL/min/1.73 m2 for patients &lt;60 years of age;

               2. &lt;40 mL/min/1.73 m2 for patients ≥60 and &lt;70 years of age; or

               3. &lt;35 mL/min/1.73 m2 for patients ≥70 years of age;

         14. Females who are pregnant or lactating;

         15. Evidence or history of any significant physical or psychiatric condition including
             drug abuse, which, in the opinion of the Investigator, could jeopardize the safety of
             patients, or affect their participation in the study. Additionally, the Investigator
             has the ability to exclude a patient if for any reason the Investigator judges the
             patient is not a good candidate for the study or will not be able to follow study
             procedures;

         16. Current participation in any investigational drug or device study or the use of any
             investigational drug or device within 30 days of the Screening Visit.

        Before randomization, all patients will receive a test dose of etripamil NS 70 mg to
        evaluate tolerability and to train patients for the procedures. A failure of the test dose
        is considered if patients meet any of the following criteria occurring after administration
        of the etripamil NS 70 mg test dose:

          1. Any symptoms consistent with clinically severe hypotension such as pre-syncope,
             medically significant lightheadedness, syncope, nausea, or vomiting;

          2. For patients with a pre-test dose Systolic Blood Pressure above 100 mmHg:

               1. Decrease in SBP ≥40 mmHg after test dose; or

               2. Post-test dose SBP &lt;80 mmHg;

          3. For patients with a pre-test dose SBP between 90 mmHg and 100 mmHg (inclusive):

             a) Post-test dose SBP &lt;75 mmHg;

          4. Third-degree AV block, Mobitz II second-degree AV block, or Wenckebach with
             bradycardia ≤40 bpm;

          5. New, significant sinus bradycardia Heart Rate ≤40 bpm or sinus pauses (≤3 seconds), if
             considered by the Investigator to put the patient's safety at risk if either were to
             occur while not under medical supervision;

          6. Any new significant ventricular arrhythmia (premature ventricular beats and couplets
             [&gt;6 premature ventricular contractions per 45 seconds ECG] are considered
             significant); and

          7. Atrial fibrillation or atrial flutter (event lasting longer than 30 seconds).

        Patients who fail the test dose will proceed in the study as follows:

          -  If the Investigator identifies a possible reversible cause of the initial test dose
             failure (e.g., concomitant medication such as beta-blocker), a re-challenge with a new
             test dose of etripamil NS 70 mg will be possible after elimination of the reversible
             cause (e.g., withdrawal of concomitant therapy with the appropriate washout period).
             Patients may be randomized if they pass the second test dose and the cause of the test
             dose failure is eliminated for the duration of the study; or

          -  If the Investigator cannot identify a reversible cause of the initial test dose
             failure, or if the potential cause cannot be modified (e.g., necessary
             antihypertensive drug to control blood pressure), patients will not be randomized and
             will complete a Final Study Visit. Patients who fail the test dose will be part of the
             Test Dose Only Population, including all patients who received at least 1 test dose of
             etripamil NS 70 mg
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Douglas Wight</last_name>
    <phone>+1-514-336-0444</phone>
    <phone_ext>226</phone_ext>
    <email>dwight@milestonepharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Francis Plat</last_name>
    <phone>1-514-336-0444</phone>
    <phone_ext>225</phone_ext>
    <email>fplat@milestonepharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Arrhythmia Research Center</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Raymond</last_name>
      <phone>602-456-2342</phone>
      <email>sraymond@azheartrhythm.com</email>
    </contact>
    <investigator>
      <last_name>Vijendra Swarup, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arkansas Cardiology</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bobbi Philips</last_name>
      <phone>501-227-7596</phone>
      <phone_ext>1263</phone_ext>
      <email>bphillips@acard.org</email>
    </contact>
    <investigator>
      <last_name>Greer Gerald, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Los Alamitos Cardiovascular</name>
      <address>
        <city>Los Alamitos</city>
        <state>California</state>
        <zip>90720</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ria Ronquillo</last_name>
      <phone>562-430-7533</phone>
      <phone_ext>223</phone_ext>
      <email>riar@losalcardio.com</email>
    </contact>
    <investigator>
      <last_name>Ramandeep Brar, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mercy General Hospital</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sammi Lewandowski</last_name>
      <phone>916-453-2682</phone>
      <email>ssammi.lewandowski@DignityHealth.org</email>
    </contact>
    <investigator>
      <last_name>Gearoid O'Neil, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mashandi Herat Institute Inc.</name>
      <address>
        <city>Stockton</city>
        <state>California</state>
        <zip>95204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mona Ameli</last_name>
      <phone>209-944-5530</phone>
      <email>m.ameli@drmashandi.com</email>
    </contact>
    <investigator>
      <last_name>Ramin Mashandi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ClinScale Management, LLC</name>
      <address>
        <city>Visalia</city>
        <state>California</state>
        <zip>93291</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Stolfi</last_name>
      <phone>559-578-4062</phone>
      <email>jessica@clinscalemanagement.com</email>
    </contact>
    <investigator>
      <last_name>Aditya Verma, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Denver Cardiology Associates, P.C</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Soltau</last_name>
      <phone>303-703-2191</phone>
      <email>msoltaue@southdenver.com</email>
    </contact>
    <investigator>
      <last_name>Roger Damle, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist Health Ambulatory Services</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Doran Cassidy</last_name>
      <phone>904-202-7218</phone>
      <email>doran.cassidy@bmcjax.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Ruisi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jacksonville Center for Clinical Research</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gail Lowe</last_name>
      <phone>904-732-6674</phone>
      <email>glowe@encoredocs.com</email>
    </contact>
    <investigator>
      <last_name>Michael Koren, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prachi Kulahalli</last_name>
      <phone>904-953-7277</phone>
      <email>kulahalli.prachi@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>K.L. Venkatachalam, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Naples Heart Rhythm Specialists, P.A</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jori Richardson</last_name>
      <phone>239-330-5670</phone>
      <email>jrichardson@naplesheartrhythm.com</email>
    </contact>
    <investigator>
      <last_name>Andrew Yin, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart Lore Susearch ; Edgewater Medical Research</name>
      <address>
        <city>New Smyrna Beach</city>
        <state>Florida</state>
        <zip>32169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Blount</last_name>
      <phone>386-426-7938</phone>
      <email>blount@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Erick Lo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charlotte Heart and Vascular Institute</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <zip>33952</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Mullinax</last_name>
      <phone>941-613-0330</phone>
      <email>kmullinax@chvifl.com</email>
    </contact>
    <investigator>
      <last_name>Sergio Cossu, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Piedmont Heart Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bola Ajose</last_name>
      <phone>404-605-2875</phone>
      <email>bola.ajose@piedmont.org</email>
    </contact>
    <investigator>
      <last_name>Bruce Stambler, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Burton</last_name>
      <phone>704-410-1116</phone>
      <email>cburton@iacthealth.com</email>
    </contact>
    <investigator>
      <last_name>Jones Sr. Alonzo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Arrythmia Consultants&amp;Research Institute</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>312012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brianna Wolfe</last_name>
      <phone>478-755-1560</phone>
      <email>bwolfe@gacri.com</email>
    </contact>
    <investigator>
      <last_name>Felix Sogade, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Arrhythmia Consultants &amp; Research Institute</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shawanna Jackson</last_name>
      <phone>240-826-6188</phone>
      <email>sjackso2@adventisthealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Sean Beinart, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Luke's Idaho Cardiology Associates</name>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheri LaMott</last_name>
      <phone>203-388-7216</phone>
      <email>lamotts@slhs.org</email>
    </contact>
    <investigator>
      <last_name>Marcos Daccarett, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60608</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sudha Lukka</last_name>
      <phone>872-222-7830</phone>
      <email>sudhalukka@prismsgrp.com</email>
    </contact>
    <investigator>
      <last_name>Sandeep Khosla, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical investigation Specialists,Inc</name>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <zip>60031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrycja Kalwajtys</last_name>
      <phone>847-599-2492</phone>
      <phone_ext>111</phone_ext>
      <email>pkalwajtys@cisreserach.com</email>
    </contact>
    <investigator>
      <last_name>Isaac Dor, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Parkview Physicians Group - Cardiology</name>
      <address>
        <city>Fort Wayne</city>
        <state>Indiana</state>
        <zip>46845</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tracy Miller</last_name>
      <phone>260-266-6628</phone>
      <email>tracy.miller@parkview.com</email>
    </contact>
    <investigator>
      <last_name>David Schleinkofer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Franciscan Physician Network - Indiana Heart Physicians</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Alford</last_name>
      <phone>317-893-1712</phone>
      <email>stephanie.alford@franciscanalliance.org</email>
    </contact>
    <investigator>
      <last_name>Robert Kinn, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Coulson</last_name>
      <phone>515-633-3843</phone>
      <email>tcoulson@iowaheart.com</email>
    </contact>
    <investigator>
      <last_name>Denise Sorrentino, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas City Cardiac Arrhythmia Research LLC</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donita Atkins</last_name>
      <phone>816-651-1969</phone>
      <email>donita.atkins@hcahealthcare.com</email>
    </contact>
    <investigator>
      <last_name>Dhanunjaya Lakkireddy, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MedStar Health Research Institute</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Yashinski</last_name>
      <phone>443-777-2369</phone>
      <email>Cynthia.L.Yashinski@medstar.net</email>
    </contact>
    <investigator>
      <last_name>Glenn Meininger, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sparrow Clinical Research Institute</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Mitchell</last_name>
      <phone>517-364-5737</phone>
      <email>sandra.mitchell@sparrow.org</email>
    </contact>
    <investigator>
      <last_name>John Ip, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension Providence Hospital</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathryn Telck</last_name>
      <phone>248-849-3104</phone>
      <email>kathryn.telck@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Nathan Foster, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester, Saint Marys Hospital</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gena Holten</last_name>
      <phone>507-255-6676</phone>
      <email>holten.gena@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Noseworthy, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Valley Hospital</name>
      <address>
        <city>Ridgewood</city>
        <state>New Jersey</state>
        <zip>07450-2736</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kimberly Michel</last_name>
      <phone>201-447-8000</phone>
      <email>kmichel@valleyhealth.com</email>
    </contact>
    <investigator>
      <last_name>Suneet Mittal, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New Mexico Heart Institute</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zinai Tellez</last_name>
      <phone>505-843-2827</phone>
      <email>zinaij@nmhi.com</email>
    </contact>
    <investigator>
      <last_name>Sean Mazer, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Trinity Medical WNY, PC</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Giambra</last_name>
      <phone>716-835-2966</phone>
      <email>tgiambra@trinitymedicalwny.org</email>
    </contact>
    <investigator>
      <last_name>Robert Gianfagna, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grace Lee</last_name>
      <phone>646-962-8493</phone>
      <email>grl2008@med.cornell.edu</email>
    </contact>
    <investigator>
      <last_name>James Ip, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Lawrence Health System: Canton-Potsdam Hospital</name>
      <address>
        <city>Potsdam</city>
        <state>New York</state>
        <zip>13676</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kylie Sands</last_name>
      <phone>315-261-6310</phone>
      <email>ksands@cphospital.org</email>
    </contact>
    <investigator>
      <last_name>Alexandru Stoian, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peak Cardiology</name>
      <address>
        <city>Apex</city>
        <state>North Carolina</state>
        <zip>27502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Barbara White</last_name>
      <phone>919-363-6060</phone>
      <email>coordinator@peakclinicaltrials.com</email>
    </contact>
    <investigator>
      <last_name>Srivani Ambati, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sanger Heart and Vascular Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jayshree Rathod</last_name>
      <phone>704-355-4794</phone>
      <email>jayshree.rathod@atriumhealth.org</email>
    </contact>
    <investigator>
      <last_name>Joseph Thompson, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Presbyterian Hospital DBA Novant Health Heart and Vascular Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Latisha Morgan</last_name>
      <phone>704-264-1400</phone>
      <email>lmorgan@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Kambur, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hatton Institute for Research &amp; Education, Trihealth, Inc. - cardiology</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Reilly</last_name>
      <phone>513-862-2877</phone>
      <email>susan_reilly2@trihealth.com</email>
    </contact>
    <investigator>
      <last_name>Gaurang Gandhi, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Ohio State University (OSU) Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adrianne Miller</last_name>
      <phone>614-688-8252</phone>
      <email>adrianne.miller3@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>Ralph Augostini, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Heart House Research Foundation, LLC</name>
      <address>
        <city>Springfield</city>
        <state>Ohio</state>
        <zip>45505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teresa Bruner</last_name>
      <phone>937-323-1404</phone>
      <email>hhrf.tbruner@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pradeep Gujja, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ProMedica Toledo Hospital</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Schmidt</last_name>
      <phone>419-842-3025</phone>
      <email>shirley.schmidt@promedica.org</email>
    </contact>
    <investigator>
      <last_name>Timothy Phelan, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiology Consultants of Philadelphia</name>
      <address>
        <city>Yardley</city>
        <state>Pennsylvania</state>
        <zip>19067</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Budzinski</last_name>
      <phone>215-321-7400</phone>
      <phone_ext>5435</phone_ext>
      <email>sharonb@ccpdocs.com</email>
    </contact>
    <investigator>
      <last_name>Christopher Schulze, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Black Hills Cardiovascular Research</name>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Anderson</last_name>
      <phone>605-755-3755</phone>
      <email>danderson14@regionalhealth.org</email>
    </contact>
    <investigator>
      <last_name>Jose Teixeira, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AIM Trials</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>83702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Waseem Chughtai</last_name>
      <phone>214-578-4983</phone>
      <email>waseem.chughtai@aimtrials.com</email>
    </contact>
    <investigator>
      <last_name>Vijay J. Jayachandran, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Harold</last_name>
      <phone>731-798-1037</phone>
      <email>harold@bcm.edu</email>
    </contact>
    <investigator>
      <last_name>Wilson Lam, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor Scott and White Research Institute - Round Rock</name>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <zip>78665</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Carter</last_name>
      <phone>512-218-6378</phone>
      <email>laura.carter@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>Javier Banchs, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scott &amp; White Memorial Hospital: Baylor Scott &amp; White Research Institute</name>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <zip>76508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wanda Fikes</last_name>
      <phone>254-724-5861</phone>
      <email>wanda.fikes@bswhealth.org</email>
    </contact>
    <investigator>
      <last_name>Greg Olsovsky, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alpine Research Organization, Inc</name>
      <address>
        <city>Layton</city>
        <state>Utah</state>
        <zip>84041</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephanie Rodriguez</last_name>
      <phone>801-928-3292</phone>
      <email>Stephanie@alpine-research.com</email>
    </contact>
    <investigator>
      <last_name>Sandeep Talwar, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IHC Health Services Inc. DBA Intermountain Medical Center</name>
      <address>
        <city>Murray</city>
        <state>Utah</state>
        <zip>84157-7000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Behunin</last_name>
      <phone>801-507-4760</phone>
      <email>Amanda.behunin@imail.org</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Anderson, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centra Cardiovascular Group</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cindy Baumann</last_name>
      <phone>434-200-2727</phone>
      <email>Cindy.Baumann@Centrahealth.com</email>
    </contact>
    <investigator>
      <last_name>Richard Kuk, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sentara Cardiovascular Research Institute</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Calayo</last_name>
      <phone>757-388-3876</phone>
      <email>cacalayo@sentara.com</email>
    </contact>
    <investigator>
      <last_name>Robert Bernstein, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University Health System</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Hockman</last_name>
      <phone>804-828-4700</phone>
      <email>melissa.hockman@vcuhealth.org</email>
    </contact>
    <investigator>
      <last_name>Kenneth Ellenbogen, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Libin Cardiovascular Institute of Alberta - University of Calgary</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer McKeage</last_name>
      <phone>403-210-6047</phone>
      <email>jmckeage@ucalgary.ca</email>
    </contact>
    <investigator>
      <last_name>Stephen Wilton, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Alexandra Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5H 3V9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Phuong Le Kvill</last_name>
      <phone>780-613-5007</phone>
      <email>phuong.le@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Evan Lockwood, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital - Research Institute ; Gordon and Leslie Diamond Health Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jackie Chow</last_name>
      <phone>604-875-5043</phone>
      <email>jackie.chow@vch.ca</email>
    </contact>
    <investigator>
      <last_name>Matthew Bennett, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Victoria Cardiac Arrhythmia Trials, Inc.</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8T 1Z4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Caitlin Patterson</last_name>
      <phone>205-595-0400</phone>
      <phone_ext>2</phone_ext>
      <email>cpatterson@catrials.org</email>
    </contact>
    <investigator>
      <last_name>Laurence Sterns, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Manitoba, St Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebbeca Fromm</last_name>
      <phone>2014-237-2380</phone>
      <email>rfromm@sbgh.mb.ca</email>
    </contact>
    <investigator>
      <last_name>Clarence Khoo, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dalhousie University - QEII Health Sciences Centre, Nova Scotia Health Authority-Halifax Infirmary</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gillian Schraefel</last_name>
      <phone>902-473-7733</phone>
      <email>Gillian.Schraefel@nshealth.ca</email>
    </contact>
    <investigator>
      <last_name>Amir Abdel-Wahab, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge Cardiac Care Centre</name>
      <address>
        <city>Cambridge</city>
        <state>Ontario</state>
        <zip>N1R 6V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Gebeyehu</last_name>
      <phone>519-624-3511</phone>
      <email>gebeyehubeth@cambridgecardiaccare.com</email>
    </contact>
    <investigator>
      <last_name>Shekhar Pandey, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dawson Road Medical Centre</name>
      <address>
        <city>Guelph</city>
        <state>Ontario</state>
        <zip>N1H 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam DeRose</last_name>
      <phone>226-337-1841</phone>
      <email>aderose@dawsonclinicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Doug Friars, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 0A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruth Chinchilla</last_name>
      <phone>905-527-4322</phone>
      <phone_ext>44450</phone_ext>
      <email>chinchill@hhsc.ca</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Healey, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Partners in Advanced Cardiac Evaluation (PACE) Cardiology Clinic</name>
      <address>
        <city>Newmarket</city>
        <state>Ontario</state>
        <zip>M2R 3V6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Nemtean</last_name>
      <phone>905 895 4521</phone>
      <email>dnemtean@rogers.com</email>
    </contact>
    <investigator>
      <last_name>Atul Verma, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manna Research</name>
      <address>
        <city>Stoney Creek</city>
        <state>Ontario</state>
        <zip>L8J 3W2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gagandeep Dhillon</last_name>
      <phone>461-294-0724</phone>
      <email>gagandeep.dhillon@lmcmanna.com</email>
    </contact>
    <investigator>
      <last_name>Sudip Datta, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marta Gadacz</last_name>
      <phone>416-864-5379</phone>
      <email>gadaczm@smh.ca</email>
    </contact>
    <investigator>
      <last_name>Victoria Korley, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Heart Institute - Institut de Cardiologie de Montréal</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronique Roy</last_name>
      <phone>514-376-3330</phone>
      <phone_ext>3315</phone_ext>
      <email>veronique.roy@icm-mhi.org</email>
    </contact>
    <investigator>
      <last_name>Blandine Mondesert, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de l'Université de Montréal (CHUM) ; CHUM Recherche Cardiologie</name>
      <address>
        <city>Montréal</city>
        <state>Quebec</state>
        <zip>H2X 0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Denis</last_name>
      <phone>514-890-8000</phone>
      <phone_ext>12790</phone_ext>
      <email>isabelle.denis.chum@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Benoit Coutu, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Universitaire de Cardiologie et de Pneumologie de Québec</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brigitte Ottinger</last_name>
      <phone>418-656-8711</phone>
      <phone_ext>3364</phone_ext>
      <email>brigitte.ottinger@criucpq.ulaval.ca</email>
    </contact>
    <investigator>
      <last_name>Karine Roy, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSSS de l'Estrie - CHUS ; Hôpital Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <state>Quebec</state>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia Vachon</last_name>
      <phone>819-346-1110</phone>
      <email>nvachon.chus@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Jean-François Roux, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>March 7, 2018</study_first_submitted>
  <study_first_submitted_qc>March 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>December 16, 2019</last_update_submitted>
  <last_update_submitted_qc>December 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paroxysmal supraventricular tachycardia</keyword>
  <keyword>cardiac monitoring</keyword>
  <keyword>atrioventricular nodal reentrant tachycardia</keyword>
  <keyword>atrioventricular reciprocating tachycardia</keyword>
  <keyword>calcium channel blocker</keyword>
  <keyword>conversion rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Supraventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

